Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash & Equivalents (2016 - 2025)

KalVista Pharmaceuticals' Cash & Equivalents history spans 11 years, with the latest figure at $131.6 million for Q2 2025.

  • On a quarterly basis, Cash & Equivalents rose 314.03% to $131.6 million in Q2 2025 year-over-year; TTM through Apr 2025 was $131.6 million, a 314.03% increase, with the full-year FY2025 number at $131.6 million, up 314.03% from a year prior.
  • Cash & Equivalents hit $131.6 million in Q2 2025 for KalVista Pharmaceuticals, down from $182.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for KALV hit a ceiling of $182.3 million in Q4 2024 and a floor of $17.7 million in Q1 2021.
  • Historically, Cash & Equivalents has averaged $61.3 million across 4 years, with a median of $49.4 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 43.47% in 2024 and later soared 314.03% in 2025.
  • Tracing KALV's Cash & Equivalents over 4 years: stood at $50.6 million in 2021, then rose by 13.98% to $57.7 million in 2023, then soared by 216.18% to $182.3 million in 2024, then decreased by 27.81% to $131.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for KALV at $131.6 million in Q2 2025, $182.3 million in Q4 2024, and $41.6 million in Q4 2024.